close

Enter

Log in using OpenID

Biotherapeutics Cell Line Development Market to Reach US

embedDownload
Biotherapeutics Cell Line Development Market to Reach US$99.84 mn by 2022, Rising Demand
for Monoclonal Antibodies Fuels Growth
According to a new market report published by Transparency Market Research “Biotherapeutics
Cell Line Development Market - Global Industry Analysis, Size, Share, Growth, Trends, and
Forecast 2015 - 2022”, the global biotherapeutics cell line development market was valued at
US$56.03 mn in 2014 and is anticipated to expand at a CAGR of 7.5% from 2015 to 2022 to reach
US$99.84 mn by 2022.
The demand for biotherapeutics is continuously increasing, because many biopharmaceutical
drugs are reaching later stage clinical trials. Most biotherapeutic drugs are recombinant
monoclonal antibodies which are widely produced in mammalian cell lines because of the need
for post-translational modifications that should be alike or at least similar to those obtained in
humans. Thus, there is an increase in the market for cell line development. Moreover,
advancements in upstream processing technologies have led to improvement in speed and
efficiency of generating robust and highly productive cell line for large scale production of protein
therapeutics and has propelled the market for cell line development.
Get a Sample Copy of Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8272
Increasing proportion of geriatric population across the globe and prevalence of various diseases
among them are the major factors driving the market. Moreover, increase in the demand for
monoclonal antibodies across the globe is another factor driving the market for biotherapeutics
cell line development.
The global biotherapeutics cell line development market is segmented by process, by cell line
development option and by geography. The market by process segment has been sub-segmented
as transfection and single cell cloning. The single cell cloning market is further segmented by
method as manual limited dilution cloning, FACS, ClonePix and Others. The market by CLD option
is segmented as In-house, outsource, hybrid and do-it-yourself. The ClonePix accounted for the
largest market share of 37.4% in 2014. Due to high throughput nature of the ClonePix, this
method is widely adopted and the market is further expected to grow in the coming years. Due
to the trend of outsourcing in this market, the market for outsourcing is expected to grow at the
highest rate in coming years.
Major players in this market are Beckton Dickinson & Company (U.S.), Beckman Coulter (U.S.),
Boehringer Ingelheim Group (Germany), Catalent Inc. (U.S.), CMC Biologics A/S (Denmark), Lonza
Group Ltd. (Switzerland), EMD Millipore (U.S.), Partec (Sysmex Corporation) (Japan), ProBioGen
AG (Germany), Selexis SA (Germany), Sigma-Aldrich Co. LLC. (U.S.), Sony Biotechnology Inc. (U.S.),
and Thermo Fisher Scientific Inc. (U.S.).
Browse Full Report: http://www.transparencymarketresearch.com/biotherapeutics-cell-linedevelopment-market.html
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business
information reports and services. Our exclusive blend of quantitative forecasting and trends
analysis provides forward-looking insight for thousands of decision makers. We have an
experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources
and various tools and techniques to gather, and analyze information. Our business offerings
represent the latest and the most reliable information indispensable for businesses to sustain a
competitive edge.
Contact
Mr. Sudip S.
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com
Author
Priya
Priya45   documents Email
Document
Category
Uncategorized
Views
0
File Size
198 KB
Tags
biotherapeutics, market, cell, line, development, reach
1/--pages
Report inappropriate content